These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 3019810)

  • 21. Bran and irritable bowel syndrome: time for reappraisal.
    Francis CY; Whorwell PJ
    Lancet; 1994 Jul; 344(8914):39-40. PubMed ID: 7912305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.
    Darvish-Damavandi M; Nikfar S; Abdollahi M
    World J Gastroenterol; 2010 Feb; 16(5):547-53. PubMed ID: 20128021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome.
    Gilbody JS; Fletcher CP; Hughes IW; Kidman SP
    Int J Clin Pract; 2000 Sep; 54(7):461-4. PubMed ID: 11070572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Bran in the treatment of irritable bowel syndrome].
    Dubinin AV; Kabanov AV; Kirkin BV; Kolkunova GK; Igorianova NA
    Vopr Pitan; 1987; (1):13-6. PubMed ID: 3031879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Domperidone treatment in the irritable bowel syndrome.
    Fielding JF
    Digestion; 1982; 23(2):125-7. PubMed ID: 6284574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The irritable colon syndrome. New therapeutic possibilities in the treatment of a frequent syndrome].
    Eisenburg J; Kruis W; Schüssler P; Weinzierl M
    Fortschr Med; 1978 Nov; 96(41):2064-70. PubMed ID: 700592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome.
    Rees G; Davies J; Thompson R; Parker M; Liepins P
    J R Soc Promot Health; 2005 Jan; 125(1):30-4. PubMed ID: 15712850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website.
    Everitt H; Moss-Morris R; Sibelli A; Tapp L; Coleman N; Yardley L; Smith P; Little P
    BMC Gastroenterol; 2013 Apr; 13():68. PubMed ID: 23602047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timolol treatment in the irritable bowel syndrome.
    Fielding JF
    Digestion; 1981; 22(3):155-8. PubMed ID: 6269935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?
    Chakraborty DS; Hazra A; Sil A; Pain S
    J Family Med Prim Care; 2019 Oct; 8(10):3173-3178. PubMed ID: 31742138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care.
    Reme SE; Kennedy T; Jones R; Darnley S; Chalder T
    J Psychosom Res; 2010 Apr; 68(4):385-8. PubMed ID: 20307706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome.
    Lüttecke K
    Curr Med Res Opin; 1980; 6(6):437-43. PubMed ID: 6988171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The treatment of irritable bowel syndrome. Two doses of mebeverine compared.
    Prout BJ
    Practitioner; 1983 Oct; 227(1384):1607-8. PubMed ID: 6356119
    [No Abstract]   [Full Text] [Related]  

  • 34. [Bran in the treatment of irritable colon. A double-blind controlled investigation].
    Soltoft J; Gudmand-Hoyer E; Krag B; Kristensen E; Wulff HR
    Ugeskr Laeger; 1976 Nov; 138(49):3316-8. PubMed ID: 793121
    [No Abstract]   [Full Text] [Related]  

  • 35. [Duodenogastric reflux in patients with irritable bowel syndrome treated with wheat bran].
    Swiatczak C; Jawień A; Swiatkowski M; Słomiński JM; Kowiański Z; Zasieczny W
    Pol Merkur Lekarski; 1998 Apr; 4(22):196-8. PubMed ID: 9770995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Determination of placebo effect in irritable bowel syndrome].
    Enck P; Klosterhalfen S; Kruis W
    Dtsch Med Wochenschr; 2005 Aug; 130(34-35):1934-7. PubMed ID: 16123895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral domperidone: double blind comparison with placebo in irritable bowel syndrome.
    Cann PA; Read NW; Holdsworth CD
    Gut; 1983 Dec; 24(12):1135-40. PubMed ID: 6357963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study.
    Goettsch WG; van den Boom G; Breekveldt-Postma NS; Smout AJ; Herings RM
    Pharmacoepidemiol Drug Saf; 2004 Nov; 13(11):803-10. PubMed ID: 15386693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.
    Bijkerk CJ; Muris JW; Knottnerus JA; Hoes AW; de Wit NJ
    Aliment Pharmacol Ther; 2004 Feb; 19(3):245-51. PubMed ID: 14984370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The non-effect of pirenzepine in dietary resistant irritable bowel syndrome.
    Gilvarry J; Kenny A; Fielding JF
    Ir J Med Sci; 1989 Oct; 158(10):262. PubMed ID: 2559903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.